NLS Isomerase Therapeutics

NeuroVive Pharmaceutical has made a partial acquisition of British company Isomerase Therapeutics with the overall goal to strengthen the partnership and accelerate NeuroVive’s research and development program. The acquisition aims to further enhance the collaboration and to ensure that NeuroVive’s projects remain a key priority for Isomerase. Furthermore, the partnership will support the discovery of new […]

NeuroVive Pharmaceutical AB has formed a new partnership with the UK’s Isomerase Therapeutics to pursue a new phase based on new molecules for its stroke medication candidate NVPO14.  NeuroVive ended its previous collaboration with to-BBB of the Netherlands at the end of 2014, following to-BBB’s restructuring and liquidation. The partnership with to-BBB was funded through a grant […]

Mitochondrial medicine company Neurovive Pharmaceutical recently announced the signing of a collaboration agreement with Isomerase Therapeutics. The agreement involves the product development and commercialization of the cyclophilin-inhibiting molecules that were recently acquired from Biotica Ltd. According to a press release, the collaboration will focus on cellular protection for traumatic brain injury and heart attack, and […]